Solar Lentigo Clinical Trial
Official title:
Evaluation of the Performance and Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in th Treatment of Brown Spots (Solar and Senile Lentigines, Post-Inflammatory Hyperpigmentation) on the Face and Hands of Asian Ethnicity Skins
Verified date | May 2023 |
Source | Cryonove Pharma |
Contact | Léa SESTITO |
Phone | 0169414764 |
l.sestito[@]bio-ec.fr | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
CS5_4 study aim to evaluate the performance and the tolerance of 3 prototypes of cyto-selective cryotherapy treatments applied on the brown spots on the face and hands of asian ethnicity skins (chinese). A brown spot is defined as solar or senile lentigo (SSL) and post-inflammatory hyperpigmentation (PIH). Each treatment corresponds to a combination of a specific sequence of cryogenic spray and of a frequency of application. Each spot will be treated by a defined prototype (always the same device on the same spot all along the study). The study will evaluate the following prototype : - Prototypes 1 - Prototypes 2 - Prototypes 3
Status | Not yet recruiting |
Enrollment | 120 |
Est. completion date | February 29, 2024 |
Est. primary completion date | February 29, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Female or male, - Chinese ethnicity skins, - Ages between 18 years old and 75 years old, - Phototype II or III (according to Fitzpatrick scale), - Featuring brown spots = 3 and = 6 mm in diameter - Agreeing not to be exposed to the sun (or artificial UV) during the study. - Informed, having undergone a general clinical examination attesting to his/her ability to participate in the study. - Having given written consent for their participation in the study. - No suspicion of carcinoma after investigation by a dermatologist. Exclusion Criteria: - Having performed cosmetic treatments (exfoliants, scrubs or self-tanners, manicures, facials, UV ...) in the month before the start of the study where the prototypes will be applied. - Having applied a depraving product in the month prior to the start of the study, where the prototypes will be applied. - Having performed cosmetic treatments in a dermatologist (laser, Intense Pulsed Light (IPL), peeling, creams, cryotherapy ...) in the last 6 months where the prototypes will be applied (see restrictions paragraph). - With dermatosis, autoimmune disease, systemic, chronic or acute disease, or any other pathology that may interfere with treatment or influence the results of the study (people with diabetes or circulatory problems, allergic to cold, Raynaud's syndrome...). - Receiving treatment by general or local (dermo corticoids, corticosteroids, diuretics ...) Likely to interfere with the evaluation of the parameter studied. - Participating in another study or being excluded from a previous study. - Unable to follow the requirements of the protocol. - Vulnerable: whose ability or freedom to give or refuse consent is limited. - Major protected by law (tutorship, curatorship, safeguarding justice...). - People unable to read and write the language of the documents involved in the study. - Unable to be contacted urgently over the phone. For female subjects: - Pregnant woman (or wishing to be pregnant during study) or while breastfeeding. - A woman who does not have a contraceptive method. |
Country | Name | City | State |
---|---|---|---|
France | Laboratoire BIO-EC | Longjumeau |
Lead Sponsor | Collaborator |
---|---|
Cryonove Pharma | CEISO |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline skin hyperpigmentation | The evaluation will be performed visually on the selected spots.
A scale in 6 points (0 to 5) will be used : 0=Clear of hyperpigmentation; Almost clear of hyperpigmentation; mild, but noticeable hyperpigmentation; moderate hyperpigmentation (medium brown in quality); severe hyperpigmentation (dark brown in quality); very severe hyperpigmentation (very dark brown, almost black in quality). |
Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, Day 91, Day 0 + 6 months | |
Primary | Change from baseline skin hypopigmentation | The evaluation will be performed visually on the selected spots.
A scale in 5 points will be used (0 to 4): 0=no hypopigmented lesion; very slight area of hypopigmentation of very small size and very slightly fairer than the surrounding skin; slight area of hypopigmentation of small size and slightly fairer than the surrounding skin; moderate : area of hypopigmentation of moderate size and much fairer than the surrounding skin; severe : area of hypopigmentation of large size and much fairer than the surrounding skin. |
Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, Day 91, Day 0 + 6 months | |
Primary | Change from baseline skin appearance - expected events | The evaluation will be performed visually on the selected spots and surrounded spotless skin area around the spot skin to assess erythema, oedema blister, bubble, scars, micro-bruise, hematoma, dryness,desquamation, fissures/cracks, roughness,crust, pink spots and papules.
A scale in 5 points (0 to 4) will be used : 0=none; very mild; mild; moderate; severe. |
Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, Day 91, Day 0 + 6 months | |
Primary | Change from baseline skin sensation | The evaluation will be performed visually on the selected spots and around the spot skin to assess tightness, stinging, itching, warm and burning sensation.
A scale in 5 points (0 to 4) will be used : 0=none; very mild; mild; moderate; severe. |
Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, Day 91, Day 0 + 6 months | |
Primary | Self-assesment of pain by VAS | The pain of the treatment will be assessed by the Visual Analogue Scale (VAS) at time T0 on the treated area.
The pain assessed is that felt during the application of the devices. It will be collected from the patient within 5 minutes of application. The VAS is made up of a 10-centimeter line anchored by two ends of the pain. 10 is the first end being the "maximum pain imaginable" and 0 is the other end being "no pain". |
Day 0 | |
Primary | Change from baseline spots visibility | Standardized photographs will be taken using a Dermatoscope C-Cube® (PIXIENCE) which allows realizing high resolution skin pictures. The capture will be taken on the previously selected lentigo and a spotless area. | Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 7, Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, Day 91, Day 0 + 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03225729 -
Assessment of CRYOBEAUTY MAINS ET DECOLLETE Versus Liquid Nitrogen Cryotherapy, in the Treatment of Solar Lentigines
|
N/A | |
Active, not recruiting |
NCT06288607 -
Safety and Efficacy of High Intensity Focused Ultrasound in Solar Lentigo: A Self-controlled Study
|
||
Recruiting |
NCT06363240 -
Evaluation of Broadband Light Treatment for Solar Lentigines
|
N/A | |
Completed |
NCT03157427 -
Clinical Evaluation of the Performance of a Difluoroethane-based Cyto-selective Cryotherapy to Treat Dark Spots on the Hand in 30 Volunteers.
|
N/A | |
Not yet recruiting |
NCT05883657 -
Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post-Inflammatory Hyperpigmentation)
|
N/A | |
Completed |
NCT05322668 -
Tolerance of Cyto-selective Difluoroethane-based Cryotherapy
|
N/A | |
Completed |
NCT05203263 -
Tolerance and Mode of Administration of Cyto-selective Cryotherapy Treatments in Face Brown Spots: Proof of Concept
|
N/A | |
Recruiting |
NCT03578315 -
Advanced Harmonic Generation Microscopy for Treatment Assessment of Cutaneous Pigmentary Disorder
|
N/A | |
Not yet recruiting |
NCT06305897 -
Evaluation of the Tolerance (Main Objective) and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post-inflammatory Hyperpigmentation) on the Face
|
N/A | |
Not yet recruiting |
NCT06361251 -
Interventional, Monocentric, Double-blind Randomized Category 2b Study Evaluating the Evaluation of the Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots (Solar and Senile Lentigines, Post -Inflammatory Hyperpigmentation (Pih)) on the Face
|
N/A | |
Completed |
NCT05625815 -
Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots.
|
N/A |